Status:
RECRUITING
Development and Prospective Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Cancer
Neoadjuvant Therapy
Eligibility:
All Genders
Brief Summary
This study is a multi-center observational study without interventions, including the construction of an AI diagnostic model and retrospective testing of a multi-center cohort. The study participants ...
Detailed Description
Bladder cancer is one of the most common malignancies of the genitourinary system worldwide. For muscle - invasive bladder cancer amenable to radical resection, the standard treatment is neoadjuvant t...
Eligibility Criteria
Inclusion
- Bladder occupying lesions, with histopathological confirmation of bladder cancer after resection.
- Planned neoadjuvant therapy and radical cystectomy.
Exclusion
- Patients who have not undergone standard bladder imaging examinations or have missing imaging or pathological data.
- Patients who have received local treatments (such as interventional embolization) or systemic treatments (such as radiotherapy, chemotherapy, immunotherapy, or targeted therapy).
- Poor quality of imaging or pathological images.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT06909643
Start Date
January 1 2022
End Date
December 31 2025
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510080